Your CFO has seen the pharmacy numbers. The conversation is coming — if it hasn't already.
GLP-1 spend is up. In some plans, it's among the fastest-growing pharmacy line items. And the questions you're getting aren't about the clinical evidence anymore. They're about the budget.
Why are we paying this much? Is it going to keep growing? Can we restrict it? What's our plan?
This post is for the person who has to answer those questions.
The Conversation You're Walking Into
If you're a benefits leader at a self-funded employer, here's what the next 90 days probably look like:
Your PBM is flagging GLP-1 utilization as a cost driver in their renewal reporting. Your broker is sending you articles about Foundayo and the Wegovy pill. Your CFO or CHRO is asking what this means for next year's budget. And somewhere in your inbox is a request to "put together a recommendation on GLP-1 coverage" before the next benefits committee meeting.
The instinct is to frame this as a coverage decision: do we cover GLP-1s for weight loss or not? But that framing is a trap, because it forces a binary answer to a question that isn't binary.
Dropping coverage entirely risks employee backlash, potential ADA considerations, and losing a tool that genuinely works for a population that needs it. Covering without guardrails risks open-ended pharmacy spend that your stop-loss carrier will notice.
The better framing — the one that actually survives a CFO conversation — is: we cover it, and here's how we make the investment durable.
What Your CFO Actually Needs to Hear
Finance leaders aren't opposed to GLP-1 coverage. They're opposed to uncontrolled spend with no measurable return. That's a reasonable position, and your job is to meet it with a plan, not a clinical argument.
Here's the framework that tends to land:
Acknowledge the cost is real and growing. Don't minimize it. If your GLP-1 spend increased 40% year-over-year, say so. If you're projecting further growth based on the two new oral options now on the market, show that projection. Credibility in this conversation starts with not sugarcoating the number.
Show that the alternative is also expensive. Untreated obesity drives costs across the plan — diabetes, cardiovascular events, musculoskeletal claims, mental health. Peterson-KFF employer focus groups show that large employers are grappling with this tradeoff. The question isn't whether obesity is costly to the plan. It's which intervention model produces the best long-term cost trajectory.
Present the durability problem as a solvable design challenge. This is where most benefits leaders lose the conversation. The CFO has read the headlines about weight regain after stopping GLP-1s. If you don't address it proactively, it becomes the objection that kills the budget request. The Oxford BMJ meta-analysis (West et al., 2026) — weight regain roughly 4x faster after stopping GLP-1s than after behavioral interventions — is data your CFO will find if you don't bring it first. Bring it first. Then present the design solution: pair coverage with a maintenance program that addresses the behavioral and metabolic foundation.
Make the maintenance layer your budget argument. This is the part most benefits leaders miss. The maintenance layer isn't an additional cost on top of GLP-1 coverage. It's the component that makes GLP-1 coverage defensible as an investment rather than a recurring expense. A program that helps employees build sustainable dietary patterns and metabolic awareness — at a fraction of the per-member cost of the medication itself — changes the ROI math from "we're paying for a drug indefinitely" to "we're paying for a drug plus a durability strategy."
The Three Scenarios to Model
When you walk into the benefits committee meeting, have three scenarios ready:
Scenario 1: Coverage with current guardrails. Whatever prior authorization or step therapy you have in place today, project forward with the two new oral GLP-1 options on the market. This is your baseline — and it's probably the number that triggered the CFO conversation in the first place.
Scenario 2: Coverage with a maintenance requirement. Model what happens if you pair GLP-1 authorization with enrollment in a metabolic health or behavioral support program. What's the added program cost? What's the projected impact on discontinuation and re-enrollment cycles? Even conservative assumptions about improved durability meaningfully change the total cost of care projection.
Scenario 3: No coverage. Model this too, even if you don't recommend it. What does your plan spend on obesity-related comorbidities without pharmacotherapy? What's the retention risk if employees perceive your benefits as behind the market? Having this scenario ready demonstrates that you've evaluated the full picture, not just the pharmacy line item.
The conversation that gets budget approval isn't "GLP-1s are clinically important." Your CFO already concedes that. The conversation that gets approval is "here's the cost under three scenarios, and here's why Scenario 2 produces the best three-year cost trajectory."
What to Bring to the Meeting
A one-page summary that covers:
The current state — what you're spending on GLP-1s, what the utilization trend looks like, what your current guardrails are.
The market context — two oral options now available, Medicare coverage launching in July at $50/month, manufacturer pricing competition driving costs down but utilization up. Keep this to two or three sentences. Your CFO doesn't need the full landscape analysis.
The three scenarios with projected costs.
Your recommendation — which scenario you're proposing and why. If you're recommending pairing coverage with a maintenance program, name the specific type of program (metabolic health, behavioral support, whatever fits your population) and the evidence base behind it.
The ask — what you need approved and by when, given the lead time for plan design changes before open enrollment.
The Timeline Is Tighter Than You Think
If your open enrollment is in Q4, the plan design decisions that shape it are being made now — in Q2 benefits committee meetings, in broker conversations, in PBM renewals. By July, your options narrow. By September, you're executing decisions that were made months earlier.
The employers who navigate GLP-1 costs well in 2027 will be the ones who treated this as a plan design question in spring 2026, not a coverage crisis in fall 2026.
The conversation with your CFO isn't a problem. It's an opportunity to design something better. Bring the data, bring the scenarios, and bring the plan. That's what gets to yes.
